State Supreme Court Rejects Challenge, Clearing Way for Stem Cell Bond Initiative
By Joyce E. Cutler,
Bureau of National Affairs
| 05. 17. 2007
The California Supreme Court refused May 16 to consider a constitutional challenge to the state stem cell initiative, clearing the way for $3 billion in bonds to be sold to fund stem cell research (People's Advocate and National Tax Limitation Foundation v. Independent Citizens Oversight Committee, Cal., No. S151574, review denied, 5/16/07).
Justices at their weekly meeting declined to review the appeal brought by opponents of California's Proposition 71, a November 2004 initiative authorizing an annual pool of $300 million to further stem cell and other medical research over a decade.
Justice Joyce Kennard voted to grant review of the decision by the California Court of Appeal, First District, upholding the initiative, according to the court docket.
A unanimous panel of the appeals court ruled last February, “we have no hesitation in concluding, in the exercise of 'our solemn duty to jealously guard the precious initiative power,’ that Proposition 71 suffers from no constitutional or other legal infirmity” (California Family Bioethics Council v. Independent Citizens' Oversight Committee, Cal. Ct. App., No. A114195; People's Advocate v. Independent Citizens' Oversight Committee, Cal...
Related Articles
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...